Publications 2011

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093.

PUBMED

Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia.

Falanga A, Russo L, Tartari CJ.

Mediterr J Hematol Infect Dis. 2011;3(1):e2011068.

PUBMED

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011;118(9):2599-601.

PUBMED

Defining the thrombotic risk in patients with myeloproliferative neoplasms.

Vianello F, Battisti A, Cella G, Marchetti M, Falanga A.

ScientificWorldJournal. 2011;11:1131-7.

PUBMED

All trans-retinoic acid modulates the procoagulant activity of human breast cancer cells.

Marchetti M, Russo L, Balducci D, Falanga A.

Thromb Res. 2011;128(4):368-74.

PUBMED

LMWH bemiparin and ULMWH RO-14 reduce the endothelial angiogenic features elicited by leukemia, lung cancer, or breast cancer cells.

Vignoli A, Marchetti M, Russo L, Cantalino E, Diani E, Bonacina G, Falanga A.

Cancer Invest. 2011;29(2):153-61.

PUBMED
Publications 2020 Publications 2019 Publications 2018 Publications 2017 Publications 2016 Publications 2015 Publications 2014 Publications 2013 Publications 2012 Publications 2011 Publications 2010 Publications 2009 Publications 2008 Publications 2007 Publications 2006